4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid | 91541-18-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid
• 英文别名: 4-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl]phenyl]-4-oxobutanoic acid
• CAS: 91541-18-3
• 化学式: C₂₄H₂₈O₈S
• 分子量: 476.5
• InChiKey: ZAKKEARLDPTRLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid 、 2,2'-氧基二[1,3-二氯丙烷] 以 氯仿 为溶剂， 反应 48.0h， 以to afford the title compound, m.p. 135°-136°的产率得到5(4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl)phenyl)-2(3H)-furanone
  参考文献：
  名称：

  Leukotriene antagonists

  摘要：

  公式为：##STR1## 的化合物是C.sub.4，D.sub.4和E.sub.4白三烯的拮抗剂，也是过敏反应缓慢反应物的拮抗剂。这些化合物可用作抗哮喘，抗过敏，抗炎和细胞保护剂。

  公开号：

  US05135940A1
• 作为产物：
  描述：

  生成 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid
  参考文献：
  名称：

  Leukotriene antagonists, their production, and compositions containing them

  摘要：

  公开号：

  EP0104885B1

文献信息

• New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2108641A1

  公开（公告）日：2009-10-14

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
  申请人：Almirall, S.A.

  公开号：EP2322176A1

  公开（公告）日：2011-05-18

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to pharmaceutical compositions comprising them, and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂，以及包含它们的药物组合物，以及它们在治疗中的应用。
• [EN] NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE 7-PHÉNYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE
  申请人：ALMIRALL SA

  公开号：WO2011057757A1

  公开（公告）日：2011-05-19

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂，涉及它们的制备方法，包括它们的药物组合物，以及它们在治疗中的应用。
• New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2113503A1

  公开（公告）日：2009-11-04

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。